CTRIP: MMPI-PARI-BASED INTERVENTIONS IN ARTERIAL THROMBOSIS

CTRIP：基于 MMPI-PARI 的动脉血栓干预措施

• 批准号: 8357837
• 负责人: Stephen F Hanson
• 金额: $ 3.63万
• 依托单位: OREGON HEALTH & SCIENCE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-05-01 至 2012-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8357837
• 关键词: Acute; Angioplasty; Biological; Disease; Dose; Drug Kinetics; F2R gene; Funding; Grant; Hemostatic Agents; Intervention; MMPI; Matrix Metalloproteinase Inhibitor; Modeling; National Center for Research Resources; Papio; Pharmacodynamics; Primates; Principal Investigator; Research; Research Infrastructure; Resources; Safety; Source; Therapeutic; Thrombosis; United States National Institutes of Health; Work; acute coronary syndrome; base; cost; drug development; novel

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. Primary support for the subproject and the subproject's principal investigator may have been provided by other sources, including other NIH sources. The Total Cost listed for the subproject likely represents the estimated amount of Center infrastructure utilized by the subproject, not direct funding provided by the NCRR grant to the subproject or subproject staff. This project is evaluating the therapeutic potential of a combined PAR1-MMP inhibitor molecule in acute thrombotic diseases. In particular, this work is part of biological drug development project for these novel compounds that are intended for use in acute coronary syndrome and angioplasty/stenting indications. The work will determine antithrombotic efficacy, hemostatic safety, pharmacodynamics (PD) and pharmacokinetics (PK) of intravenously administered escalating doses of PZ-128 in baboon models of arterial thrombosis.

该子项目是利用资源的众多研究子项目之一 由 NIH/NCRR 资助的中心拨款提供。子项目的主要支持 并且子项目的主要研究者可能是由其他来源提供的， 包括其他 NIH 来源。 子项目可能列出的总成本 代表子项目使用的中心基础设施的估计数量， NCRR 赠款不直接向子项目或子项目工作人员提供资金。 该项目正在评估联合 PAR1-MMP 抑制剂分子在急性血栓性疾病中的治疗潜力。特别是，这项工作是这些新型化合物生物药物开发项目的一部分，这些化合物旨在用于急性冠状动脉综合征和血管成形术/支架置入术。这项工作将确定在狒狒动脉血栓模型中静脉注射递增剂量的 PZ-128 的抗血栓功效、止血安全性、药效学 (PD) 和药代动力学 (PK)。